The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR Guidance on Tocilizumab Allocation During Shortage

ACR Guidance on Tocilizumab Allocation During Shortage

September 1, 2021 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In June, the U.S. Food & Drug Administration (FDA) issued an emergency use authorization (EUA) for tocilizumab (Actemra) for treatment of hospitalized COVID-19 adults and children who are receiving systemic corticosteroids and supplemental oxygen. Since this announcement, the tocilizumab manufacturer, Genentech, has not been able to produce enough product to meet the higher demand. The ACR recognizes the importance of this treatment for patients with rheumatoid arthritis and other conditions. The ACR practice and advocacy team is in constant communication with the FDA and the manufacturer to highlight the urgency of the tocilizumab shortage and the impact on rheumatology patients, and to ensure we are able to provide the most up-to-date information.

You Might Also Like
  • Quinacrine Shortage & What the ACR Is Doing about It
  • ACR Update on Tocilizumab Shortages
  • Tocilizumab Begins Clinical Trial for COVID-19
Also By This Author
  • Rheumatology Research Foundation Reaches $60 Million Journey to Cure Goal

As we continue to navigate this shortage, the ACR has finalized guiding principles on the allocation of intravenous tocilizumab. The ACR has sent letters to the nation’s 30 largest payers urging them to refrain from imposing utilization management tools on this class of therapies to ensure patients have access to their treatment, and to temporarily permit off-label use of alternative therapies with similar mechanism of action to avoid loss of access and prevent disease flares and irreversible patient harm. The ACR will also continue to engage with the FDA, Genentech and the Centers for Medicare & Medicaid Services on such issues as wastage reimbursement.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Genentech has created a customer service website dedicated to this issue, including new ordering procedures. The ACR will provide additional information as it becomes available. Contact [email protected] with any questions.

Filed Under: Drug Updates, Legislation & Advocacy Tagged With: COVID-19, Drug shortage, tocilizumab

You Might Also Like:
  • Quinacrine Shortage & What the ACR Is Doing about It
  • ACR Update on Tocilizumab Shortages
  • Tocilizumab Begins Clinical Trial for COVID-19
  • Tocilizumab Fails to Help COVID-19 Patients in Italian Study

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)